Eisai opens doors at $200M cancer drug R&D shop

After committing $200 million to the personalized cancer R&D unit, Japanese drugmaker Eisai officially opened the doors of the group, called H3 Biomedicine, in Cambridge, MA, this week. H3 Biomedicine, which aims to discover cancer drugs that attack the specific drivers of patients' tumors, plans to build up its staff to 70 people over the next year and expand beyond its 24,000 square feet of lab space. The group now employs 30 workers. Article | Release

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.